

E. G. Manzhaliy, V. E. Kondratiuk

*A. A. Bogomolets National Medical University Ministry of Health Ukraine,
01601, Kyiv*

INCREASING EFFICACY OF TREATMENT PATIENTS WITH STEATOHEPATITIS

The results of a study of 33 patients with nonalcoholic steatohepatitis, 24 — alcoholic steatohepatitis, and 18 — drug-induced liver injury are presented. In patients with liver injury changes in intestinal microflora were marked. After a combination therapy of this pathology with *L*-ornithine-*L*-aspartate and symbiotic, an improvement of biochemical, clinical indicators was observed, as well as a decrease in fatty degeneration, reduction of elastographic indicators of liver fibrosis. The introduction of the drug formulation *L*-ornithine-*L*-aspartate and symbiotic in the complex of conservative treatment of steatohepatitis help to prevent complications and increase the treatment efficacy of these diseases.

Keywords: *L*-ornithine-*L*-aspartate, *Lactobacillus casei*, *Bifidobacterium longum*, fruktooligosaccharides, steatohepatitis, endotoxins.

Obesity and metabolic syndrome are increasing in the population, and so is nonalcoholic steatohepatitis. Continuous and recurrent course of hepatic diseases and their complications is accompanied by a progressive structural and functional damage of these organs and is accompanied by a significant decrease in quality of life that allows to consider these diseases in terms of an important medical and social problem and envisages the search for new directions of improving treatment and prevention of this pathology [6, 8, 9, 13].

The course of hepatic diseases is often accompanied by the damage to the intestinal microflora that contributes to the development of metabolic disorders and chronic intoxication. Excessive accumulation of free radicals and lipid peroxidation products is one of the leading pathogenetic mechanisms of hepatocellular lesions due to the damage to the lipid layer of cell membranes and metabolic disorders in the liver with the subsequent development of biliary insufficiency [1, 5, 12]. Bacterial overgrowth syndrome plays an important role in the development of hepatic steatosis [10].

Ammonia has been the most studied gut-derived neurotoxin, produced from the breakdown of proteins and amino acids. Ammonia is produced by the gastrointestinal tract in two ways: by direct ammonia liberation from breakdown products of dietary protein and metabolism of circulating glutamine (GLN) and by the gut microbiome acting upon urea and ingested food. Concentrations of ammonia are kept relatively constant in the blood by efficient detoxification processes, involving hepatic production of urea and synthesis of GLN from glutamate (GLU) by the action of glutamine synthetase (EC 6.3.1.2 — GS), which is located in the liver, muscle, and brain. Hyperammonemia is commonly seen in chronic liver disease, as are high levels of circulating endotoxins, as the liver fails to detoxify the portal circulation draining the intestines, which are heavily colonized by metabolically active bacteria, or else because the portal blood supply bypasses the liver through the development of a collateral circulation in the presence of portal hypertension. In addition, damage to the liver and the intestine can result from side effects of drugs: nonsteroidal anti-inflammatory glucocorticoids, salazopyrazins, statins, antihypertensives etc. [2, 3, 13].

The practical importance of this paper consists in clarifying the mechanisms of progression of steatohepatitis, improving the efficacy of this pathology treatment with the use of a *L*-ornithine-*L*-aspartate (*LOLA*) and symbiotic (prebiotic + probiotic). *LOLA* is a treatment directed at removal of circulating ammonia. Ornithine promotes hepatic removal of ammonia by stimulating residual hepatic urea cycle activity through action of ornithine carbamoyltransferase and carbamoylphosphate synthetase. Additionally, ornithine and aspartate are both substrates for the urea cycle. In perivenous hepatocytes, ornithine and aspartate combine with α -ketoglutarate to produce GLU. GLU is used by skeletal muscle and brain to use ammonia, via the action of GS to produce GLN, reducing the amount of circulating ammonia. Prebiotics are nondigestible food ingredients, stimulating growth of select colonic bacteria to improve host health, whereas probiotics are live microbial food supplement improving host gut microbial balance. Symbiotics are a combination of the two [4, 10].

The study objective is — evaluation of the treatment efficacy of steatohepatitis using Larnamin (*L*-ornithine-*L*-aspartate) and Lactiale (*Lactobacillus casei*, *Lactobacillus rhamnosus*, *Streptococcus thermophilus*, *Bifidobacterium longum*, *Lactobacillus bulgaricus* — $1,0 \cdot 10^8$ per capsule — with fruktooligosaccharides).

Examined patients and methods. Seventy-five patients (36 % men, 64 % women aged 25 to 67 years) with steatohepatitis have been examined in the gastroenterology department, including those with nonalcoholic steatohepatitis (NASH) — 33 (44 %), alcoholic steatohepatitis (ASH) — 24 (32 %), drug-induced liver injury (DILI) — 18 (24 %). For establishing accurate diagnosis of liver injury standard diagnostic criteria were used for NASH [4, 10], ASH [7] and DILI [4]. Seventy-eight percent of the patients had obesity, 37 % — type 2 diabetes. The body mass index varied from 17.8 to 33.7 kg/m². According to the principles of the Helsinki Declaration, all the

patients were fully apprised of the subject matter of treatment and the drug properties.

The diagnosis was verified on the basis of a complex of clinical laboratory studies (general clinical tests, intestinal endoscopy, coprogram and stool culture, fractional multi-moment duodenal intubation). To study the functional state of the liver, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGTP) activity, the levels of cholesterol, triglycerides, high-, low and very low density lipoproteins, total and direct bilirubin, blood total proteins, fasting glycaemia and glycemia 2 hours after glucose challenge, blood pressure were studied; insulin resistance index was calculated. All patients underwent ultrasound investigation (apparatus Aixplorer[®], Supersonic Imagine, France) with shear wave elastography, which allows to get objective information about the stiffness, elastic properties of the liver tissue during a routine real-time ultrasonic scan. The presence of hepatic fibrosis was determined by the propagation of elastic waves of 20–30 ultrasonic pulses followed by calculating the average values of the deformation pressure (in kPa) [11]. Patients with viral hepatic lesions (hepatitis *B*, *C* viral markers, Epstein — Barr virus, and cytomegalovirus), autoimmune hepatitises were not enrolled in the study. To exclude helminthic invasion, chlamydiosis, toxoplasmosis, enzyme immunoassay was used.

All patients, depending on the treatment, were assigned into 2 groups: in the experimental group, in addition to the basic therapy, Larnamin and Lactiale were administered (L&L treatment); the patients in the control group remained on basic therapy without L&L treatment. Each group was subdivided into three subgroups depending on the first-listed diagnosis (NASH, ASH, DILI). All analyzed subgroups were equivalent by diagnosis, age and sex. Basic therapy included the low animal fat diet (30–90 g/day) and with restriction of particularly rapidly digestible fats (150 mg/day). As a part of basic treatment, the patients received behavioral therapy and adequate physical activity for 30 minutes/day.

According to the the L&L treatment, the LOLA and symbiotic were administered for 3 months.

The statistical processing was performed by means of the SPSS 13 system.

Results and their discussion. Our findings indicates, that after treatment of liver injury in two experimental groups (basic therapy with L&L treatment) patients were diagnosed with the significantly decreased manifestation of syndromes (table 1). However, under the L&L treatment the percentage of patients with diagnosed symptoms was extremely less (see table 1).

Under the influence of the treatment (see table 1), an amelioration of biochemical indicators, which characterize the condition of the liver, was showed. The frequency of significant changes was higher in the groups receiving L&L treatment as compared to those without them.

During the study of hepatic parenchymal elasticity in patients receiving L&L treatment, positive dynamics were noted. In patients with NASH after treatment, the indicators were (5.7 ± 0.8) kPa, which corresponds to F0–F1

Table 1

Dynamics of biochemical parameters after the L&L treatment of liver diseases

| Parameter | NASH (n = 33) | | | ASH (n = 24) | | | DILI (n = 18) | | |
|--------------------------------|------------------|--------------------------|---------------------|------------------|--------------------------|---------------------|------------------|--------------------------|---------------------|
| | Before treatment | After standard treatment | After L&L treatment | Before treatment | After standard treatment | After L&L treatment | Before treatment | After standard treatment | After L&L treatment |
| Total bilirubin <i>mmol/l</i> | 18.7 ± 2.4* | 17.0 ± 2.1* | 12.0 ± 2.4** | 31.0 ± 2.8* | 22.0 ± 0.7* | 16 ± 2.4**α | 24.7 ± 2.4* | 23.8 ± 2.3* | 18 ± 2.5 **α |
| Direct bilirubin <i>mmol/l</i> | 7.0 ± 0.4* | 5.9 ± 0.7* | 3.5 ± 0.6**α | 6.7 ± 0.3* | 6.1 ± 0.4** | 3.8 ± 0.5**α | 7.0 ± 0.4* | 6.5 ± 0.4* | 3.4 ± 0.6 **α |
| ALT, <i>IU/l</i> | 45.0 ± 1.7* | 39.0 ± 2.5** | 24.0 ± 2.4**α | 64.0 ± 2.3* | 47.0 ± 2.9** | 22 ± 2.7**α | 84 ± 2.4* | 56.0 ± 2.8** | 32 ± 2.4**α |
| AST, <i>IU/l</i> | 40.0 ± 2.1* | 35.0 ± 2.8** | 22.0 ± 2.3**α | 72.0 ± 1.4* | 54.0 ± 2.2** | 32 ± 2.9**α | 67 ± 3.2* | 39.0 ± 3.4** | 34 ± 2.3**α |
| GGTP, <i>IU/l</i> | 37.8 ± 2.1* | 29.0 ± 1.9** | 19.1 ± 2.4**α | 87.1 ± 2.7* | 69.0 ± 2.6** | 27.6 ± 2.9**α | 53.8 ± 2.1* | 30.1 ± 2.6** | 19.1 ± 2.4**α |
| Cholesterol, <i>mmol/l</i> | 7.1 ± 0.4* | 6.7 ± 0.8* | 5.4 ± 0.7**α | 6.4 ± 0.6* | 5.9 ± 0.8* | 4.9 ± 0.6**α | 6.1 ± 0.4* | 5.7 ± 0.5* | 5.4 ± 0.7* |
| Total proteins, <i>g/l</i> | 55.0 ± 3.0* | 56.0 ± 5.0* | 60.0 ± 3.0* | 59.0 ± 7.0* | 60.0 ± 5.0* | 62.0 ± 4.0 | 55.0 ± 3.0* | 58.0 ± 4.0* | 60 ± 3.0* |

Notes: (here and in table 2) * — $P < 0.001$ as compared with healthy people; # — $P < 0.05$ as compared with patients before treatment; α — $P < 0.05$ as compared with standard treated patients.

stage of hepatic fibrosis, according to Metavir scale and is significantly lower than the indicators in the patients before treatment — (6.7 ± 1.3) kPa, F1 according to Metavir scale at $P < 0.001$.

In patients with ASH, the indicators after treatment were (6.1 ± 0.8) kPa, which corresponds to F0–F1 stage of hepatic fibrosis, according to Metavir scale and is significantly lower than the indicators in the patients before treatment — (7.8 ± 1.1) kPa (F1 according to Metavir scale) at $P < 0.001$ and (5.7 ± 1.1) kPa in patients with DILI after treatment, which corresponds to F0–F1 stage of hepatic fibrosis according to Metavir scale and is significantly lower than the indicators in the patients before treatment — (6.5 ± 1.1) kPa (F1 according to Metavir scale at $P < 0.001$.

After combination therapy with the use of Larnamine and Lactiale, in stool culture of 52 % of patients, the growth of Bifidobacteria was noted, as well as the growth of Lactobacteria in 67 % of patients; also a significant decrease in the number of Staphylococci, yeasts, Bacteroides, Protei, Cyto-bacter, Klebsiellae in 42 % of patients (table 2). These results indicated greater potency of the L&L treatment for restoration of microflora in patients compared to standard scheme.

Table 2
The percentage of patients with altered intestinal microflora composition after the L&L treatment of liver diseases

| Microflora | NASH (n = 33) | | | ASH (n = 24) | | | DILI (n = 18) | | | |
|---|-----------------------------|--------------------------|---------------------|------------------|--------------------------|---------------------|-------------------|--------------------------|---------------------|-------------------|
| | Before treatment | After standard treatment | After L&L treatment | Before treatment | After standard treatment | After L&L treatment | Before treatment | After standard treatment | After L&L treatment | |
| Bifido-bacteria | Normal, $>10^7$ CFU/g | 17* | 37* [#] | 73 ^{#α} | 11* | 12* | 64* ^{#α} | 19* | 35* [#] | 53* ^{#α} |
| | Below normal, $<10^7$ CFU/g | 67* | 33* [#] | 25 ^{#α} | 61* | 68* | 34* ^{#α} | 57* | 52* | 38* ^{#α} |
| | Absent | 16* | 30* [#] | 2 ^α | 28* | 20* [#] | 2 ^{#α} | 24* | 13* [#] | 9* [#] |
| Lacto-bacteria | Normal, $>10^7$ CFU/g | 6* | 41* [#] | 64 ^α | 18* | 24* | 68* ^{#α} | 14 | 47* [#] | 76 ^{#α} |
| | Below normal, $<10^7$ CFU/g | 52* | 32* [#] | 23 ^α | 71* | 59* [#] | 21 ^{#α} | 72* | 39* [#] | 24 ^{#α} |
| | Absent | 42* | 27* [#] | 13* ^α | 11* | 17* [#] | 11 ^{#α} | 14* | 14* | 0 ^{#α} |
| Pathogenic or opportunistic pathogenic microflora | 72* | 38* [#] | 12 ^α | 63* | 40* [#] | 25* ^{#α} | 71* | 62* | 15 ^{#α} | |

As our data show, L&L treatment should be included into treatment complexes in patients with steatohepatitides of various aetiology. The L&L treatment prevents further spread of pathologic microflora and accelerates recovery.

Conclusions

1. Under the influence of the drug formulation Larnamine and Lactiale, a normalisation of the intestinal microflora is observed, which has a positive effect on the functioning of the liver and the intestines, as well as an improvement of biochemical indicators, which is evidence of the activation of membrane enzymes necessary for normalisation of carbohydrate, fat and protein metabolism, reduction of manifestations of fatty degeneration; also, a decrease in the indicators on elastographic of liver is observed.
2. The use of Larnamine and Lactiale in combination therapy in patients with NASH, ASH, DILI contributes to enhancement of the anti-inflammatory, hepatoprotective effect and the normalisation of the intestinal microflora.

References

1. *Bataller R., Rombouts K., Altamirano J., Marra F.* Fibrosis in alcoholic and nonalcoholic steatohepatitis // *Best Pract. Res. Clin. Gastroenterol.* — 2011. — 25. — P. 231–244.
2. *Baykova I. E., Nikitin I. G.* Drug liver // *Russ. Med. Zhurn.* — 2009. — 1. — P. 1–3.

3. *Bueverov A. O., Eshanu V. S., Maevskaia M. V., Ivashkin V. T.* Essential phospholipids in the treatment of mixed origin steatohepatitis // *Klin. Perspekt. Gastroenterol. Gepatol.* — 2008. — № 1. — P. 17–22.
4. *Drapkina O. M., Korneeva O. H., Ivashkin V. T.* Therapy of nonalcoholic steatohepatitis and metabolic syndrome: focus on essential phospholipids // *Lechaschiy Vrach.* — 2010. — № 2. — P. 18–24.
5. *Gerok V., Blum Kh. E.* Liver and biliary system. — M.: MEDpress-inform, 2009. — 199 p.
6. *Gong G., Xiang L., Yuan L. et al.* Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats // *PLoS One.* — 2014. — doi: 10.1371/journal.pone.0089450.
7. *Khomeriki S. G., Khomeriki N. M.* Alcoholic liver disease: pathogenesis, morphological manifestations, differential diagnosis and pathogenetic approaches to therapy // *Gastroenterologiya.* — 2012. — № 1. — P. 54–68.
8. *Machado M. V., Cortez-Pinto H.* Non-alcoholic fatty liver disease: what the clinician needs to know // *World J. Gastroenterol.* — 2014. — **20**, № 36. — P. 12956–12980.
9. *Neuman M. G., French S. W., French B. A. et al.* Alcoholic and non-alcoholic steatohepatitis // *Exp. Mol. Pathol.* — 2014. — **97**, № 3. — P. 492–510.
10. *Polunina T. E., Maev I. V.* Nonalcoholic fatty liver disease: epidemiology, pathogenesis, diagnosis, treatment // *Gastroenterologiya.* — 2012. — № 1. — P. 35–40.
11. *Velkov V. V.* Non-invasive biomarkers of fibrosis. Good-bye, biopsy?. — M.: Diiakon, 2009. — 40 p.
12. *Weiler S., Merz M., Kullak-Ublick G. A.* Drug-induced liver injury: the dawn of biomarkers? // *F1000Prime Rep.* — 2015. — **7**. — doi: 10.12703/P7-34.
13. *Weismuller T. J., Lankisch T. O.* Biliary diseases — new insights and developments // *Dtsch. Med. Wochenschr.* — 2011. — **136**. — P. 713–716.

Received 20.02.2016

ПІДВИЩЕННЯ ЕФЕКТИВНОСТІ ЛІКУВАННЯ ХВОРИХ НА СТЕАТОГЕПАТИТИ

Е. Г. Манжалій, В. Є. Кондратюк

Національний медичний університет ім. О. О. Богомольця
МОЗ України, 01601 Київ

Наведено результати обстеження 33 хворих на неалкогольний стеатогепатит, 24 — на алкогольний стеатогепатит та 18 — на лікарсько-індуковані пошкодження печінки. У хворих із стеатогепатитами різної етіології були відзначені зміни мікрофлори кишечника. Кишковий дисбіоз є основним джерелом ендотоксемії у хворих на стеатогепатити. Після комбінованої терапії даної патології *L*-орнітином-*L*-аспартатом і симбіотиком, спостерігалось поліпшення біохімічних, клінічних показників, та зниження жорсткості паренхіми печінки за даними еластографії і нормалізація мікрофлори кишечника. Використання *L*-орнітину-*L*-аспартату і симбіотика в ком-

плексах консервативного лікування стеатогепатитів допомагає запобігти розвитку ускладнень і підвищити ефективність лікування цих захворювань.

ПОВЫШЕНИЕ ЭФФЕКТИВНОСТИ ЛЕЧЕНИЯ БОЛЬНЫХ СТЕАТОГЕПАТИТАМИ

Э. Г. Манжалий, В. Е. Кондратюк

Национальный медицинский университет
им. А. А. Богомольца МЗ Украины, 01601 Киев

Приведены результаты обследования 33 больных неалкогольным стеатогепатитом, 24 — алкогольным стеатогепатитом и 18 — лекарственными повреждениями печени. У больных с этими повреждениями печени были отмечены изменения в микрофлоре кишечника. Кишечный дисбиоз является основным источником эндотоксемии у больных стеатогепатитами. После комбинированной терапии данной патологии *L*-орнитинном-*L*-аспартатом и симбиотиком, наблюдалась нормализация биохимических и клинических показателей, а также отмечалось снижение жесткости паренхимы печени (по данным эластографии) и нормализация микрофлоры кишечника. Использование *L*-орнитина-*L*-аспартата и симбиотика в комплексах консервативного лечения стеатогепатитов помогает предотвратить развитие осложнений и повысить эффективность лечения этих заболеваний.

Information about authors

Department of propedeutic of internal medicine № 2

V. E. Kondratiuk — head of department, Dr.Med.Sci.

E. G. Manzhaliy — assistant of, PhD (elinam@ukr.net)